SUPERNUS PHARMACEUTICALS INC (SUPN) Stock Price, Quote, News and Overview
NASDAQ:SUPN - Nasdaq - US8684591089 - Common Stock - Currency: USD
SUPN Quote, Performance and Key Statistics
SUPERNUS PHARMACEUTICALS INC
NASDAQ:SUPN (2/11/2025, 2:36:58 PM)
38.2153
+0.29 (+0.75%)
The current stock price of SUPN is 38.2153 USD. In the past month the price increased by 1.17%. In the past year, price increased by 33.46%.
SUPN Latest News and Analysis
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s...
Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women
Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women
Updated label includes new data in Section 12.2, detailing serotonin 5-HT2C partial agonist activity and norepinephrine transporter inhibition,...
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference
SUPN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.08 | 827.81B | ||
| JNJ | JOHNSON & JOHNSON | 15.6 | 375.23B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 26.63 | 373.60B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.21 | 226.21B | ||
| MRK | MERCK & CO. INC. | 11.34 | 219.19B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.76 | 215.64B | ||
| PFE | PFIZER INC | 8.22 | 144.82B | ||
| SNY | SANOFI-ADR | 13.59 | 134.95B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 49.2 | 113.75B | ||
| ZTS | ZOETIS INC | 30.22 | 78.54B | ||
| GSK | GSK PLC-SPON ADR | 7.82 | 73.57B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 30.56 | 42.63B |
Related stock screener links
About SUPN
Company Profile
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. The company is headquartered in Rockville, Maryland and currently employs 652 full-time employees. The company went IPO on 2010-12-28. The firm is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The firm is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.
Company Info
SUPERNUS PHARMACEUTICALS INC
9715 Key West Avenue
Rockville MARYLAND 20850 US
CEO: JACK A. KHATTAR
Employees: 652
Company Website: https://www.supernus.com
Investor Relations: https://ir.supernus.com/
Phone: 13018382500
SUPN FAQ
What is the stock price of SUPN?
The current stock price of SUPN is 38.2153 USD.
What is the symbol for SUPERNUS PHARMACEUTICALS INC stock?
The exchange symbol of SUPERNUS PHARMACEUTICALS INC is SUPN and it is listed on the Nasdaq exchange.
On which exchange is SUPN stock listed?
SUPN stock is listed on the Nasdaq exchange.
Is SUPN a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for SUPN, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of SUPN.
Does SUPN stock pay dividends?
SUPN does not pay a dividend.
When does SUPN stock report earnings?
SUPN will report earnings on 2025-03-04, after the market close.
What is the Price/Earnings (PE) ratio of SUPN?
The PE ratio for SUPN is 17.37. This is based on the reported non-GAAP earnings per share of 2.2 and the current share price of 38.2153 USD.
What is the Short Interest ratio of SUPN stock?
The outstanding short interest for SUPN is 11.47% of its float.
SUPN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to SUPN. When comparing the yearly performance of all stocks, SUPN is one of the better performing stocks in the market, outperforming 83.3% of all stocks.
SUPN Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to SUPN. Both the health and profitability get an excellent rating, making SUPN a very profitable company, without any liquidiy or solvency issues.
SUPN Financial Highlights
Over the last trailing twelve months SUPN reported a non-GAAP Earnings per Share(EPS) of 2.2. The EPS increased by 134.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 9.16% | ||
| ROA | 4.45% | ||
| ROE | 5.93% | ||
| Debt/Equity | 0 |
SUPN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to SUPN. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 108.13% and a revenue growth 7.46% for SUPN